STC3141 / China Grand Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
STC3141 / China Grand Pharma
Sepsis, NCT06548854: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploration Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Characteristics of STC314 Injection Administered Intravenously in Patients

Active, not recruiting
2
180
RoW
STC314 Injection/STC314 Injection Placebo, STC314 Injection Placebo
Grand Medical Pty Ltd.
Sepsis
11/24
02/25
NCT05000671: A Study to Evaluate the Safety and Effect of STC314 Injection Continuous Infusion in Subjects With Acute Respiratory Distress Syndrome

Recruiting
1
16
RoW
STC314 injection or Placebo(rate=58.3 mg/hr), STC314 injection or Placebo(rate=87.5 mg/hr)
Grand Medical Pty Ltd., Grand Pharmaceutical (China) Co., Ltd.
Acute Respiratory Distress Syndrome
12/22
12/22
ACTRN12620000716965: A Open Label Study to Determine the Safety, Tolerability and Pharmacokinetics of STC3141 Administered as an Infusion for up to 72 hours in Subjects in an Intensive Care Unit

Completed
1
26
 
Grand Medical Pty Ltd, Grand Medical
sepsis
 
 

Download Options